Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny DNA fragments in blood could reveal how aggressive a pancreatic tumor will be

NCT ID NCT07817225

Diagnosis Sponsor: Massimo Falconi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

Pancreatic neuroendocrine tumors behave unpredictably: some stay slow for years while others spread quickly, and doctors lack reliable tests to tell them apart before surgery. This study examines cell-free DNA, tiny genetic fragments shed by tumors into the bloodstream, from about 30 patients whose plasma samples are stored in a hospital biobank. Researchers will map chemical tags and fragment patterns on that DNA to see whether they match how aggressive each person's tumor turned out to be. The goal is to learn whether a blood test could one day help guide monitoring and treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cell-free DNA molecular profiling of stored blood plasma
What this could lead to
If the DNA patterns line up with tumor behavior, doctors could one day use a simple blood draw to judge how aggressive a pancreatic neuroendocrine tumor is and tailor monitoring or treatment.
What could go wrong
This is a small, retrospective lab study of about 30 stored samples, so it can only show associations, not prove the test works. The findings may not hold in larger or different groups, and no patient receives treatment or direct benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Sep 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include approximately 30 adult patients diagnosed with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs) whose biological samples are available through the HSR NETBank biobank. Participants will represent three distinct clinical subgroups: patients under active surveillance and patients who underwent surgical resection with a histopathological diagnosis of either indolent or aggressive disease. All included patients have provided informed consent for the use of their biological material and clinical data for research purposes.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Diagnosis of sporadic, well-differentiated, non-functioning pancreatic neuroendocrine tumor (NF-PanNET). * Signed informed consent for the use of plasma samples stored in the "NETbank" biobank. * Availability of pre-operative or surveillance plasma samples. Exclusion Criteria: * Genetic syndromes associated with NF-PanNETs (e.g., MEN1, VHL). * Functioning PanNETs. * Inadequate quality or quantity of circulating-free DNA (cfDNA) extracted from plasma samples.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-functioning pancreatic neuroendocrine tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell non-functional pancreatic neuroendocrine tumor pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic neuroendocrine tumor

Contacts and locations

Locations

  • IRCCS San Raffaele

    Milan, MI, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.